News and Announcements
Kazia selected as top-10 finalist in the ANZLF Trans-Tasman Innovation & Growth Awards
- Published September 05, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Kazia is pleased to announce they have been selected as a top-10 finalist in the ANZLF Trans-Tasman Innovation & Growth Awards.
The Awards celebrate the innovation, growth and impact of emerging businesses in Australia and New Zealand and Kazia was recognised for its strong growth story, diverse and collaborative culture and its innovative programs for brain and ovarian cancer.
The Awards are run by the Australia New Zealand Leadership Forum (ANZLF) which brings senior business and government leaders together to help Australia and New Zealand prosper in the global economy.
The four Award winners will be announced at a dinner in Auckland, New Zealand next Thursday, September 12. The Awards will be presented by New Zealand Prime Minister, Jacinda Ardern.
For more information on Kazia register your interest below.
About Kazia Therapeutics (ASX: KZA)
Kazia Therapeutics is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. Headquartered
in Sydney, Australia, Kazia Therapeutics collaborates with leading scientists, clinicians, and investors around the world.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
